IRBM Reports Breakthrough in Zika Virus Drug Discovery
ROME, Feb. 10, 2026 /PRNewswire/ -- IRBM, a leader in early drug discovery research, has announced a major scientific breakthrough with the discovery of a novel and potent allosteric inhibitor targeting the Zika virus (ZIKV) protease (NS2B-NS3). The...
Coway Discloses Implementation Assessment of Its Corporate Value-Up Plan
Since announcing its Corporate Value-Up Plan in 2025, Coway has been seeing tangible progress across revenue growth, shareholder returns, financial soundness and governance To date, the company has executed KRW 247.3 billion in shareholder returns,...
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. Unlike...
Autozi Signs Cooperation Agreement with the Suizhou Special Purpose Vehicle Chamber of Commerce, Targeting US$2 Billion and Forging Another Major Milestone in the Company's Development History.
BEIJING, Jan. 29, 2026 /PRNewswire/ -- Autozi (Stock ticker: AZI), a leading operator of automotive industry supply chain cloud platforms in China, signed a strategic cooperation agreement today with the Hubei Suizhou Special Purpose Vehicle (SPV)...
BOSGAME Launches Next-Generation AI PCs Built on AMD and Intel Platforms, Targeting High-Performance Compact Computing
SHENZHEN, China, Jan. 15, 2026 /PRNewswire/ -- BOSGAME, a technology-based electronic product brand, has officially announced the launch of two new AI PC models, the VTA-439 and VTI-490, marking a strategic move aligned with the latest technology...
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the...
Ractigen Therapeutics Announces First Patient Dosed in Phase II Clinical Trial of RAG-17 for SOD1-ALS
NANTONG, China, Jan. 13, 2026 /PRNewswire/ -- Ractigen Therapeutics is pleased to announce that the first patient has been dosed in the Phase II clinical trial of RAG-17, an innovative siRNA therapy targeting SOD1-mutated amyotrophic lateral...
CapitaLand India Data Centre Fund to acquire 20.2% interest in three data centres for S$99.73 million
The development-focused data centre fund raised approximately S$150 million equity at first close SINGAPORE, Jan. 12, 2026 /PRNewswire/ -- CapitaLand Investment Limited (CLI), a leading global real asset manager, has successfully raised...
ACEN completes transition to 100% renewable energy
MANILA, Philippines, Dec. 29, 2025 /PRNewswire/ -- ACEN has reached a defining milestone in its transformation journey, having achieved 100% renewable energy generation across its portfolio earlier this year. The milestone underscores a strategic...
Highway Holdings Plans to Acquire 51% of Regent-Feinbau Adermann GmbH
HONG KONG, Dec. 23, 2025 /PRNewswire/ -- Highway Holdings Limited (Nasdaq: HIHO, the "Company" or "Highway Holdings") today announced it has signed a letter of intent ("LOI") with LeMALe Beteiligungs-GmbH ("LeMaLe" or "Seller") to acquire 51% of...